GB0210212D0 - Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability - Google Patents

Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability

Info

Publication number
GB0210212D0
GB0210212D0 GBGB0210212.7A GB0210212A GB0210212D0 GB 0210212 D0 GB0210212 D0 GB 0210212D0 GB 0210212 A GB0210212 A GB 0210212A GB 0210212 D0 GB0210212 D0 GB 0210212D0
Authority
GB
United Kingdom
Prior art keywords
dietary
effects
atheromatous plaque
plaque stability
pufa intake
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0210212.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pronova Biopharma Norge AS
Original Assignee
University of Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southampton filed Critical University of Southampton
Priority to GBGB0210212.7A priority Critical patent/GB0210212D0/en
Publication of GB0210212D0 publication Critical patent/GB0210212D0/en
Priority to GB0307625A priority patent/GB2388026B/en
Priority to NZ536507A priority patent/NZ536507A/en
Priority to NZ548508A priority patent/NZ548508A/en
Priority to DE60329588T priority patent/DE60329588D1/en
Priority to AU2003229993A priority patent/AU2003229993B2/en
Priority to EP03722833A priority patent/EP1501493B1/en
Priority to CN03815692XA priority patent/CN1665496B/en
Priority to PCT/GB2003/001945 priority patent/WO2003092673A1/en
Priority to AT03722833T priority patent/ATE444745T1/en
Priority to BR0309740-4A priority patent/BR0309740A/en
Priority to JP2004500857A priority patent/JP4688203B2/en
Priority to ES03722833T priority patent/ES2334656T3/en
Priority to CA2485116A priority patent/CA2485116C/en
Priority to IL16498404A priority patent/IL164984A0/en
Priority to US10/979,751 priority patent/US8729124B2/en
Priority to NO20045275A priority patent/NO334959B1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Fats And Perfumes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

<WC 1><WC 1><WC 1><WC 1><WC 1>Use of the n-3 polyunsaturated fatty acids EPA and /or DHA in the preparation of an oral medicament for preventing cerebral damage in patients having symptoms of atherosclerosis of arteries supplying the brain.
GBGB0210212.7A 2002-03-05 2002-05-03 Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability Ceased GB0210212D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB0210212.7A GB0210212D0 (en) 2002-05-03 2002-05-03 Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
GB0307625A GB2388026B (en) 2002-05-03 2003-04-02 Use of epa and dha in secondary prevention of neurological events,particulary strokes
CA2485116A CA2485116C (en) 2002-05-03 2003-05-02 Use of epa and dha in secondary prevention
PCT/GB2003/001945 WO2003092673A1 (en) 2002-05-03 2003-05-02 Use of epa and dha in secondary prevention
AT03722833T ATE444745T1 (en) 2002-05-03 2003-05-02 USE OF EPA AND DHA FOR SECONDARY PREVENTION OF STROKE
DE60329588T DE60329588D1 (en) 2002-05-03 2003-05-02 USE OF EPA AND DHA FOR SECONDARY PREVENTION OF STROKE
AU2003229993A AU2003229993B2 (en) 2002-05-03 2003-05-02 Use of EPA and DHA in secondary prevention
EP03722833A EP1501493B1 (en) 2002-05-03 2003-05-02 Use of epa and dha in secondary prevention of strokes
CN03815692XA CN1665496B (en) 2002-05-03 2003-05-02 Use of EPA and DHA in Preparation of medicinie for secondary prevention of neurogenic diseases
NZ536507A NZ536507A (en) 2002-05-03 2003-05-02 Use of eicosapentaenoic acid or docosahexaenoic acid or fish oil for prevention of cerebral damage in patients having symptoms of atherosclerosis or arteries supplying the brain i.e stroke
NZ548508A NZ548508A (en) 2002-05-03 2003-05-02 Use of EPA and DHA in preventing cerebral damage wherein the dosage ranges from 0.5 to 5.0g of EPA and/or DHA daily
BR0309740-4A BR0309740A (en) 2002-05-03 2003-05-02 Use of eicosapentaenoic acid (epa), docosaexaenoic acid (dha) or a mixture of epa and dha or a pharmaceutically acceptable salt or derivative thereof
JP2004500857A JP4688203B2 (en) 2002-05-03 2003-05-02 Drugs using eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in secondary brain disease events such as stroke
ES03722833T ES2334656T3 (en) 2002-05-03 2003-05-02 USE OF EPA AND DHA IN SECONDARY PREVENTION OF BRAIN SPILLS.
US10/979,751 US8729124B2 (en) 2002-03-05 2004-11-02 Use of EPA and DHA in secondary prevention
IL16498404A IL164984A0 (en) 2002-05-03 2004-11-02 Use of epa and dha in secondary prevention
NO20045275A NO334959B1 (en) 2002-05-03 2004-12-01 Use of EPA and DHA in secondary prevention

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0210212.7A GB0210212D0 (en) 2002-05-03 2002-05-03 Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability

Publications (1)

Publication Number Publication Date
GB0210212D0 true GB0210212D0 (en) 2002-06-12

Family

ID=9936057

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0210212.7A Ceased GB0210212D0 (en) 2002-03-05 2002-05-03 Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
GB0307625A Expired - Fee Related GB2388026B (en) 2002-03-05 2003-04-02 Use of epa and dha in secondary prevention of neurological events,particulary strokes

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB0307625A Expired - Fee Related GB2388026B (en) 2002-03-05 2003-04-02 Use of epa and dha in secondary prevention of neurological events,particulary strokes

Country Status (6)

Country Link
JP (1) JP4688203B2 (en)
AT (1) ATE444745T1 (en)
DE (1) DE60329588D1 (en)
ES (1) ES2334656T3 (en)
GB (2) GB0210212D0 (en)
NZ (1) NZ536507A (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070149617A1 (en) 2005-11-14 2007-06-28 Deckelbaum Richard J Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
CA2571462C (en) 2006-02-07 2013-08-13 Mochida Pharmaceutical Co., Ltd. Composition for preventing recurrence of stroke
PL2046312T3 (en) * 2006-07-14 2021-02-08 Kaydence Pharma As Pharmaceutical and nutraceutical products comprising vitamin k2
AU2009315314B2 (en) * 2008-11-14 2013-04-18 Bomi P. Framroze A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis
NZ595204A (en) 2009-03-09 2014-11-28 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
KR102354949B1 (en) * 2009-10-23 2022-01-24 바스프 에이에스 Coated capsules and tablets of a fatty acid oil mixture
CN105263321B (en) 2013-03-28 2018-07-27 哥伦比亚大学纽约管理委员会 Promote the protection to the donor organ for transplanting with omega-3 glyceride Reperfu- sions
EP3263113A1 (en) * 2016-06-30 2018-01-03 Jürgen Mertin Use and composition (comprising colecalciferol, omega-3-fatty acid and ginkgo biloba) for maintaining and improving cognitive functions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2218904A (en) * 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
JP2534557B2 (en) * 1989-03-30 1996-09-18 全国農業協同組合連合会 Method for producing feed for pork and pork for meat
JPH05271685A (en) * 1991-12-26 1993-10-19 Shokuhin Sangyo High Separeeshiyon Syst Gijutsu Kenkyu Kumiai Oil or fat composition containing highly unsaturated fatty acid and production of glyceride oil containing highly unsaturated fatty acid
IT1264987B1 (en) * 1993-12-14 1996-10-17 Prospa Bv SALTS OF A POLYUNSATURATED FATTY ACID AND PHARMACEUTICAL FORMULATIONS THAT CONTAIN THEM
IT1274734B (en) * 1994-08-25 1997-07-24 Prospa Bv PHARMACEUTICAL COMPOSITIONS CONTAINING POLYUNSATURATED FATTY ACIDS, THEIR ESTERS OR SALTS, WITH VITAMINS OR ANTIOXIDANT PROVITAMINS
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
JPH1180083A (en) * 1997-09-10 1999-03-23 Nof Corp Production of eicosapentaenoic ester
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
JP2000159678A (en) * 1998-11-30 2000-06-13 Nof Corp Ointment preparation
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
IT1308613B1 (en) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS.
JP2001131088A (en) * 1999-11-02 2001-05-15 Kyurin:Kk Therapeutic agent for syndrome x
EP1278540B1 (en) * 2000-05-05 2008-05-14 Laboratoires Serono SA Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders

Also Published As

Publication number Publication date
GB2388026A (en) 2003-11-05
GB2388026B (en) 2006-02-08
NZ536507A (en) 2008-12-24
ES2334656T3 (en) 2010-03-15
JP2005529903A (en) 2005-10-06
JP4688203B2 (en) 2011-05-25
GB0307625D0 (en) 2003-05-07
DE60329588D1 (en) 2009-11-19
ATE444745T1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
BR0309740A (en) Use of eicosapentaenoic acid (epa), docosaexaenoic acid (dha) or a mixture of epa and dha or a pharmaceutically acceptable salt or derivative thereof
AU7175496A (en) Edible fat-spread
HK1058883A1 (en) Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin&#39;s lymphoma and psychiatric or neurological disorders.
PT1152755E (en) ESSENTIAL FATTY ACIDS INTENDED FOR THE PREVENTION OF CARDIOVASCULAR ACCIDENTS
NZ299464A (en) Use of gamma linolenic or dihomogamma linolenic acid in the treatment of Huntington&#39;s Chorea
HK1033541A1 (en) Fat blend
EP2216318A3 (en) Resolvins: Biotemplates for therapeutic interventions
HK1020316A1 (en) Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
EP0815735A3 (en) Dietary balanced milk product
WO2007070611A3 (en) Nutritional supplement containing long-chain polyunsaturated fatty acids
YU59303A (en) Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy
IL125502A (en) Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids
IL151970A0 (en) Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
EP0764405A3 (en) Nutritional composition
GB0210212D0 (en) Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
Sadovsky Omega-3 Fatty Acids and CHD Prevention
Hrboticky et al. α-Linolenic acid combined with lovastatin elevates docosahexaenoic acid (DHA, c22: 6n-3) in cellular lipids and lipoproteins of Hep G2 cells
MY129218A (en) Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: PRONOVA BIOCARE AS

Free format text: FORMER APPLICANT(S): UNIVERSITY OF SOUTHAMPTON

AT Applications terminated before publication under section 16(1)